Navigation Links
Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
Date:3/11/2008

other current assets 1,140,000 1,188,000

Total current assets 24,913,000 19,898,000

PROPERTY:

Leasehold improvements 669,000 646,000

Laboratory equipment 3,756,000 3,533,000

Furniture, fixtures and office equipment 913,000 873,000

5,338,000 5,052,000

Less accumulated depreciation and

amortization (3,537,000) (3,212,000)

Property, net 1,801,000 1,840,000

Other assets 1,527,000 1,259,000

TOTAL ASSETS $28,241,000 $22,997,000

PEREGRINE PHARMACEUTICALS, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS (continued)

JANUARY 31, APRIL 30,

2008 2007

Unaudited

LIABILITIES AND STOCKHOLDERS' EQUITY

CURRENT LIABILITIES:

Accounts payable $2,387,000 $1,683,000

Accrued clinical trial site fees 244,000 228,000

Accrued legal and accounting fees 390,000 392,000

Accrued royalties and license fees 124,000 337,000

Accrued payroll and related costs 858,000 874,000

Notes payable, current portion - 379,000

Capital lease obligation, current portion 17,000 17,000

Deferred revenue 1,434,000 1,060,000

Other current liabilities 1,239,000 885,000

Total current liabilities 6,693,000 5,855,000

Notes pay
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Peregrine Pharmaceuticals to Announce Third Quarter FY 2008 Financial Results
2. Publication in Clinical Cancer Research Confirms Ability of Peregrines Bavituximab to Target Tumor Blood Vessels with Excellent Specificity
3. Peregrine Pharmaceuticals Doses First Patient in Phase II Clinical Trial of Bavituximab in Patients With Advanced Breast Cancer
4. Peregrine Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
5. Peregrine Pharmaceuticals Remains on Track to Advance its Three Lead Clinical Programs in 2008
6. Defense Threat Reduction Agency Halts Contract Negotiations With Peregrine Pharmaceuticals as It Suffers $100 Million Cut in FY 2008 Budget for Its Transformational Medical Technologies Initiative (TMTI) Program
7. Peregrine Pharmaceuticals to Announce Second Quarter FY 2008 Financial Results
8. New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrines Anti-PS Technology Platform
9. Peregrine Pharmaceuticals to Announce First Quarter FY 2008 Financial Results
10. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
11. Alseres Pharmaceuticals Presents Inosine and Dopamine Transporter (DAT) Blocker Preclinical Data at the American Society for Experimental NeuroTherapeutics (ASENT) Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... Calif., July 10, 2014   Ceres, Inc . ... seed company, announced today financial results for the three ... on its business. Ceres reported that the ... product performance this growing season in Brazil, which concluded ... the company,s sorghum evaluation areas for part of the ...
(Date:7/10/2014)... new study published today in the journal PNAS ... found that time of day and sleep deprivation have ... be crucial when looking at the best time of ... heart disease, and for administering medicines effectively. , Researchers ... Cancer Research, London, investigated the links between sleep deprivation, ...
(Date:7/10/2014)... and spiders can sit upside down forever. Nanophysics makes sure ... in an article just published in Physical Review E ... Geckos and spiders that seem to be able to sit ... worldwide for many years. We will soon be able to ... the gecko,s foot. But the fact is, sooner or later ...
(Date:1/15/2014)... , Using an approach akin to assembling a ... Standards and Technology (NIST) researchers have succeeded in ... reduces the flammability of foam commonly used in ... flammability of the nanotube-coated polyurethane foam was reduced ...
Breaking Biology Technology:Ceres Announces Fiscal Third Quarter 2014 Financial Results 2Ceres Announces Fiscal Third Quarter 2014 Financial Results 3Ceres Announces Fiscal Third Quarter 2014 Financial Results 4Ceres Announces Fiscal Third Quarter 2014 Financial Results 5Ceres Announces Fiscal Third Quarter 2014 Financial Results 6Ceres Announces Fiscal Third Quarter 2014 Financial Results 7Ceres Announces Fiscal Third Quarter 2014 Financial Results 8Ceres Announces Fiscal Third Quarter 2014 Financial Results 9Time of day crucial to accurately test for diseases, new research finds 2Even geckos can lose their grip 2Layered security: Carbon nanotubes promise improved flame-resistant coating 2
... OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI ) announced today ... BIO Investor Forum on Wednesday, October 6 at 10:30 a.m. ... Live webcasts from this conference will be available through ... http://ir.oncogenex.com . Webcast replays will be available approximately two ...
... Inc. (PDL) (Nasdaq: PDLI ) today announced that ... of $0.50 per share to all stockholders owning shares of ... As previously announced, the conversion rate for the ... adjusted to 140.571 shares of common stock per $1,000 principal ...
... the United States became infected with West Nile virus, a potentially ... the Culex mosquito that has first fed ... in their salivary glands and transmit the disease to humans and ... the genetic makeup of the Culex mosquito, and how ...
Cached Biology Technology:OncoGenex Pharmaceuticals to Present at the 9th Annual BIO Investor Forum 2Researchers sequence genome of mosquito that spreads West Nile virus 2Researchers sequence genome of mosquito that spreads West Nile virus 3
(Date:7/11/2014)... 11, 2014 The increased risk of kidney injury ... resuscitation fluids reflects the mass of HES molecules, according ... official journal of the International Anesthesia Research Society (IARS). ... harmful effect of HES on cultured human renal proximal ... Christian Wunder and colleagues of University Hospital Wrzburg, Austria. ...
(Date:7/11/2014)... Research and Markets has announced ... - Industry Analysis Size Share Growth Trends and Forecast ... http://photos.prnewswire.com/prnh/20130307/600769 The rising ... need for high level security in both private and ... as username and passwords, tokens etc. are vulnerable to ...
(Date:7/10/2014)... , June 27, 2014  Pomerantz LLP has ... Inc. ("Provectus" or the "Company")(NYSE-MKT: PVCT) and certain ... United States District Court, Middle District of ... behalf of a class consisting of all persons ... securities between December 17, 2013 and May 22, ...
Breaking Biology News(10 mins):In lab studies, hydroxyethyl starch has direct harmful effects on kidney cells 2International Biometrics Technology Market - Industry Analysis Size Share Growth Trends and Forecast to 2019 2SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Provectus Biopharmaceuticals, Inc. and Certain Officers - PVCT 2SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Provectus Biopharmaceuticals, Inc. and Certain Officers - PVCT 3
... -- In the middle of the South Pacific, about ... that soon will emerge as a model ecosystem, thanks ... by University of California, Berkeley, biologists. Moorea, home ... Research Station and France,s Centre de Recherches Insulaires et ...
... NEW YORK (Dec. 7, 2007) -- Alcohol triggers the ... the health and activity of brain cells, and new ... City sheds light on how that process occurs. ... The Journal of Neuroscience, may also edge scientists closer ...
... researchers at The University of Nottingham are teaming up ... region, to work on pioneering Sport PhD courses. ... the use of illegal performance-enhancing drugs in sports, and ... affordable. Theyre just two of seven collaborative ...
Cached Biology News:US-French research team to barcode an entire ecosystem 2US-French research team to barcode an entire ecosystem 3US-French research team to barcode an entire ecosystem 4Research reveals secrets of alcohol's effect on brain cells 2Research reveals secrets of alcohol's effect on brain cells 3
Human Xg Affinity Purified Polyclonal Ab Keywords: Xg glycoprotein, hereditary hemorrhagic telangiectasia Protein Family: ...
in vitro Translation, Accessory Products...
...
Mouse Collagen IV...
Biology Products: